CA1137989A - Substituted pyranone inhibitors of cholesterol synthesis - Google Patents

Substituted pyranone inhibitors of cholesterol synthesis

Info

Publication number
CA1137989A
CA1137989A CA000358416A CA358416A CA1137989A CA 1137989 A CA1137989 A CA 1137989A CA 000358416 A CA000358416 A CA 000358416A CA 358416 A CA358416 A CA 358416A CA 1137989 A CA1137989 A CA 1137989A
Authority
CA
Canada
Prior art keywords
dichloro
preparation
hydroxy
mmole
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000358416A
Other languages
English (en)
French (fr)
Inventor
Alvin K. Willard
Frederick C. Novello
William F. Hoffman
Edward J. Cragoe, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of CA1137989A publication Critical patent/CA1137989A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C67/347—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to unsaturated carbon-to-carbon bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA000358416A 1979-08-17 1980-08-15 Substituted pyranone inhibitors of cholesterol synthesis Expired CA1137989A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6757479A 1979-08-17 1979-08-17
US67,574 1979-08-17

Publications (1)

Publication Number Publication Date
CA1137989A true CA1137989A (en) 1982-12-21

Family

ID=22076933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000358416A Expired CA1137989A (en) 1979-08-17 1980-08-15 Substituted pyranone inhibitors of cholesterol synthesis

Country Status (24)

Country Link
EP (1) EP0024348B1 (enExample)
JP (1) JPS5645470A (enExample)
KR (1) KR840002170B1 (enExample)
AT (1) ATE16487T1 (enExample)
AU (1) AU6108580A (enExample)
CA (1) CA1137989A (enExample)
CS (1) CS219921B2 (enExample)
DD (1) DD152558A5 (enExample)
DE (1) DE3071230D1 (enExample)
DK (1) DK353680A (enExample)
ES (1) ES494301A0 (enExample)
FI (1) FI802582A7 (enExample)
GR (1) GR69938B (enExample)
HU (1) HU182190B (enExample)
IE (1) IE50789B1 (enExample)
IL (1) IL60751A (enExample)
MA (1) MA18929A1 (enExample)
NO (1) NO155491C (enExample)
NZ (1) NZ194557A (enExample)
PL (2) PL127979B1 (enExample)
PT (1) PT71672B (enExample)
YU (1) YU207180A (enExample)
ZA (1) ZA805016B (enExample)
ZW (1) ZW19080A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440927A (en) * 1981-06-19 1984-04-03 Merck & Co., Inc. Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon
EP0068038B1 (en) * 1981-06-29 1985-09-25 Merck & Co. Inc. (+)-(4r,6s)-(e)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2h-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
US4588820A (en) * 1984-06-11 1986-05-13 Merck & Co., Inc. Process for epimerization at C6 of 3,4,5,6-tetrahydro-2H-pyran-2-one
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
DE3615620A1 (de) * 1986-05-09 1987-11-12 Hoechst Ag 4(r)-substituierte 6(s)-phenoxymethyl-, 6(s)-(beta)-phenylaethyl-und 6(s)-(beta)-styryl-tetrahydropyran-2-one, ein hochstereoselektives verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US5169976A (en) * 1987-11-25 1992-12-08 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5093363A (en) * 1989-08-22 1992-03-03 Shionogi & Co., Ltd. 2,4,6-substituted phenol derivatives
JP3171931B2 (ja) * 1992-06-02 2001-06-04 高砂香料工業株式会社 （Ｒ）−（−）−４−シアノ−３−ヒドロキシ酪酸ｔ−ブチルエステル及びその製造方法
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
RU2563831C1 (ru) * 2014-10-13 2015-09-20 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук Применение протатран 4-хлор-2-метилфеноксиацетата (хлоркрезацина) для угнетения активности холестеролэстеразы
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559180A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent

Also Published As

Publication number Publication date
IE801732L (en) 1981-02-17
HU182190B (en) 1983-12-28
MA18929A1 (fr) 1981-04-01
PL226285A1 (enExample) 1981-03-27
IL60751A0 (en) 1980-10-26
NO155491C (no) 1987-04-08
PL132249B1 (en) 1985-02-28
KR830003465A (ko) 1983-06-20
CS219921B2 (en) 1983-03-25
PT71672A (en) 1980-09-01
PT71672B (en) 1982-01-22
IE50789B1 (en) 1986-07-23
ZA805016B (en) 1982-03-31
EP0024348B1 (en) 1985-11-13
JPS5645470A (en) 1981-04-25
JPH0257550B2 (enExample) 1990-12-05
IL60751A (en) 1985-04-30
DD152558A5 (de) 1981-12-02
AU6108580A (en) 1981-02-19
NO802431L (no) 1981-02-18
NZ194557A (en) 1984-09-28
FI802582A7 (fi) 1981-02-18
ES8106152A1 (es) 1981-07-16
NO155491B (no) 1986-12-29
DE3071230D1 (en) 1985-12-19
ES494301A0 (es) 1981-07-16
GR69938B (enExample) 1982-07-21
EP0024348A1 (en) 1981-03-04
DK353680A (da) 1981-02-19
YU207180A (en) 1983-02-28
ZW19080A1 (en) 1982-03-17
PL127979B1 (en) 1983-12-31
KR840002170B1 (ko) 1984-11-26
ATE16487T1 (de) 1985-11-15

Similar Documents

Publication Publication Date Title
US4375475A (en) Substituted pyranone inhibitors of cholesterol synthesis
US4567289A (en) Substituted pyranone inhibitors of cholesterol synthesis
US4459422A (en) Substituted pyranone inhibitors of cholesterol synthesis
CA1137989A (en) Substituted pyranone inhibitors of cholesterol synthesis
US4710513A (en) Substituted pyranone inhibitors of cholesterol synthesis
KR960009434B1 (ko) 3-데메틸메발론산 유도체, 이의 제조방법 및 중간체
US5081136A (en) 1,2,3-triazole compounds active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
US4639464A (en) Antihypertensive substituted imidazole derivatives
US5473075A (en) Diastereomer salt of optically active quinolinemevalonic acid
US4308378A (en) Cis/trans isomerization of 6-(substituted-aryl-ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-ones
US3532752A (en) 1-alkylidene-3-indenyl aliphatic amines
US4946841A (en) Pyridazine 3,5-dihydroxy carboxylic acids and derivatives thereof, the use thereof for hypercholesterolemia
EP0068038B1 (en) (+)-(4r,6s)-(e)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2h-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
US5004747A (en) Isoquinolinones
US4503072A (en) Antihypercholesterolemic compounds
US4085222A (en) Pharmaceutical compositions containing 1,3-dioxanes
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
US4927851A (en) Analogs of mevalonolactone and derivatives thereof
US4751235A (en) Anti-atherosclerotic indolizine derivatives
US5599952A (en) Methods of producing carboxylic acid ester derivatives and intermediates for use in the methods
US5055484A (en) 7(1h-pyrrol-3-yl)-substituted 3,5-dihydroxyhept-6-enoic acids, 7-(1h-pyrrol-3-yl)-substituted 3,5-dihyroxyhept-anoic acids, their corresponding delta-lactones and salts, their use as medicaments and pharmaceutical products and intermediates
US4472426A (en) Antihypercholesterolemic compounds
US4322563A (en) Substituted biphenyl-2-carboxaldehydes
CA1171424A (en) ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
US4927944A (en) Antihypercholesterolemic nitrile compounds

Legal Events

Date Code Title Description
MKEX Expiry